ARA-290 (10mg)

Innate Repair Receptor Agonist | Cibinetide

The 4Balance Codex: Selective Neuro-Regeneration and Inflammation Control.

Product Overview

ARA-290 is a synthetic 11-amino acid peptide derived from the helix-B surface domain of Erythropoietin (EPO). Unlike its parent molecule, ARA-290 is engineered to be non-erythropoietic, meaning it does not stimulate the production of red blood cells (hematopoiesis). This allows for the targeted activation of tissue repair pathways without the cardiovascular risks associated with elevated hematocrit/blood viscosity. It is the primary research agent for investigating the modulation of the Innate Repair Receptor (IRR).

Format: 10mg Lyophilized Powder Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH Purity: >99% (HPLC Analysis)

Mechanism of Action: The Innate Repair Receptor (IRR)

ARA-290 functions through a highly specific receptor interaction that triggers an immediate anti-inflammatory cascade.

1. Heteromeric Binding: The peptide acts as a specific agonist for the Innate Repair Receptor (IRR), a heterocomplex formed by the Erythropoietin Receptor (EPOR) and the Beta-Common Receptor (CD131 or βc).

2. Signal Transduction: Upon binding to the IRR, ARA-290 initiates downstream signaling that inhibits the activation of NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells).

3. Pathological Interruption: By blocking NF-κB, the peptide effectively "turns off" the production of pro-inflammatory cytokines (TNF-α, IL-6) and blocks the pain signals associated with neuropathic inflammation. Crucially, because it does not bind to the EPOR homodimer, it has zero effect on hemoglobin levels.

Research Applications

In the 4Balance Research Array, ARA-290 is utilized to study the repair of small nerve fibers and the management of chronic neuropathic conditions.

• Small Fiber Neuropathy (SFN): Clinical research indicates ARA-290 can promote the regrowth of intra-epidermal nerve fibers and corneal nerve fibers (CNF), offering a potential reversal of damage in SFN models (often associated with Sarcoidosis and Diabetes).

• Allodynia & Hyperalgesia: Used to investigate the reduction of mechanical hypersensitivity and neuropathic pain states where traditional opioids are ineffective.

• Metabolic Regulation: Studies in Type 2 Diabetes models suggest improvements in HbA1c and lipid profiles alongside neuroprotection.

Research Note: The plasma half-life of ARA-290 is short (approx. 20 minutes), but the activation of the IRR triggers a sustained "genomic switch" that maintains tissue-protective effects for up to 24 hours.

Technical Specifications

• Molecular Formula: C₅₁H₈₄N₁₆O₂₁

• Molecular Mass: 1257.3 g/mol

• Vial Quantity: 10mg

• Solubility: Water Soluble (Requires Bacteriostatic Water for reconstitution)

• Storage: Store lyophilized at -20°C. After reconstitution, keep refrigerated (2°C to 8°C) and use within 1 week due to the peptide's unique stability profile.

References

1. Brines, M., et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine.

2. Dahan, A., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine.

3. Heij, L., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Sarcoidosis Vasculitis and Diffuse Lung Diseases.

4. Culver, D. A., et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science.

5. Brines, M. & Cerami, A. (2012). The innate repair receptor: a new therapeutic target for inflammation and tissue injury. Seminars in Immunology.

DISCLAIMER: FOR RESEARCH USE ONLY. This product is a laboratory reagent intended strictly for in-vitro research and development. It is not for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law.